Mercado de Linfangioleiomiomatose (LAM) da América do Norte – Tendências do setor e previsão para 2028

Análise de Mercado e Insights: Mercado de Linfangioleiomiomatose (LAM) da América do Norte

 Espera-se que o mercado norte-americano de Linfangioleiomiomatose (LAM) ganhe crescimento de mercado no período de previsão de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 4,5% no período de previsão de 2021 a 2028 e prevê-se que atinja os 66,25 milhões de dólares até 2028, contra 47,57 milhões de dólares em 2020.

A linfangioleiomiomatose (LAM) é uma doença pulmonar quística crónica rara que afeta o sistema pulmonar, o sistema renal e o sistema linfático. O sistema linfático consiste numa rede coordenada de vasos, responsável pelo transporte do fluido linfático e das células imunitárias por todo o organismo. A LAM ocorre na população feminina. As mulheres com idades compreendidas entre os 20 e os 40 anos são diagnosticadas com LAM. Cerca de 30% das mulheres com esclerose tuberosa são propensas à LAM. Ocorre frequentemente devido à mutação do complexo da esclerose tuberosa (TSC), gene TSC 1. O LAM isolado ou esporádico refere-se à ocorrência de LAM isoladamente.

A linfangiogeliomiomatose é causada pelas alterações mutantes nos dois respetivos genes, o TSC 1 e o TSC 2. A primeira forma de mutação é hereditária e ocorre em doentes com esclerose tuberosa. A segunda forma não está associada à esclerose tuberosa, denominada LAM esporádica. As pessoas com LAM esporádica também apresentam mutações genéticas, mas as mutações genéticas não são hereditárias e não podem ser transmitidas às crianças. A razão pela qual estas mutações genéticas ocorrem não é clara.

O aumento da prevalência de doenças pulmonares císticas crónicas, aumento do angiomiolipoma e esclerose tuberosa nas mulheres e aumento nos ensaios clínicos. Preparar o caminho para o crescimento do mercado da linfangioleiomiomatose (LAM). Além disso, o potencial de crescimento nas economias emergentes para a linfangioleiomiomatose (LAM) e o aumento de produtos (máquinas de diagnóstico e medicamentos genéricos) reforça o crescimento do mercado da linfangioleiomiomatose (LAM). No entanto, o aumento do custo do tratamento da LAM, as regulamentações rigorosas impostas e a inacessibilidade da linfangioleiomiomatose (LAM) aos países em desenvolvimento são as restrições que podem dificultar o crescimento do mercado. As inconsistências no material utilizado são as restrições que podem dificultar o crescimento do mercado.

The North America lymphangioleiomyomatosis (LAM )market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological The lymphangioleiomyomatosis (LAM )market report provides details of market share, new developments, and impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

North America Lymphangioleiomyomatosis (LAM ) Market Scope and Market Size

North America lymphangioleiomyomatosis (LAM ) market is segmented on the basis of product, method, wound type, and end user The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of disease type, the global lymphangioleiomyomatosis (LAM) market is segmented into tuberous sclerosis complex lam and sporadic lam Mechanical products are further segmented into monofilament fibre pad, gauze, paraffin tulle, and wet-to-dry debridement. In 2021, the tuberous sclerosis complex lam segment is dominating the global lymphangioleiomyomatosis (LAM) market due to the increased prevalence of lam in patients with tuberous sclerosis are predicted to dominate the market.
• On the basis of type, the global lymphangioleiomyomatosis (LAM ) market is segmented into diagnosis and treatment. The diagnosis segment is further segmented into blood test (vascular endothelial growth factor d (vegf-d)) and imaging test, lung function test, lung biopsy test, and others. The imaging test is further sub segmented into chest x-rays, chest CT scans, MRI of abdomen, and others. The lung biopsy test is further sub-segmented into transbronchial lung biopsy and video-assisted thorascopic lung biopsy. The treatment segment is further segmented into medication, oxygen therapy, and lung transplantation. The medication is further sub-segmented into mtor inhibitors and bronchodilators. The mtor inhibitors are further sub-segmented into sirolimus/ rapamycin, everolimus and others. The bronchodilators are further sub-segmented into albuterol, formoterol, salmeterol, and others. The lung transplantation is further sub-segmented into single-lung transplantation (SLT) and bilateral lung transplantation (BLT). In 2021 the treatment segment is dominating the global lymphangioleiomyomatosis (LAM) market owing to the rise in the number of cases and availability of generics, diagnostic and lung transplants.
• On the basis of complications, the global lymphangioleiomyomatosis (LAM) market is segmented into pneumothorax, chylothorax, kidney tumor, pleural effusions, swelling & fluid build-up, and others. In 2021, the pneumothorax segment is expected to dominate the global lymphangioleiomyomatosis (LAM) market due to the increased prevalence of female patients suffering from the chronic obstructive pulomonary disorder in the U.S., and timely diagnosis and treatment are predicted to dominate the market.
• On the basis of route of administration, the global lymphangioleiomyomatosis (LAM) market is segmented into oral, parenteral.The oral segment is further segmented into tablet, capsules, and others. The parenteral segment is further segmented into intravenous subcutaneous and others. In 2021, the oral segment is expected to dominate the global lymphangioleiomyomatosis (LAM) market due to the ease of absorption , and the medication being cost effective in the U.S. are predicted to dominate the market.
• On the basis of end users, the global lymphangioleiomyomatosis (LAM) market is segmented into hospitals, specialty clinics, diagnostic centers, home healthcare and others. In 2021, the hospitals segment is expected to dominate the global lymphangioleiomyomatosis (LAM) market due to the rise of diagnostics for lung disorders in the U.S., and the affordability of generic medications are predicted to dominate the market.
• On the basis of distribution channel, the global lymphangioleiomyomatosis (LAM) market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies and others. In 2021, the direct tender segment is expected to dominate the global lymphangioleiomyomatosis (LAM) market due to the rise in access to sirolimus medications, the surge in the number of prescriptions daily, and the rise in the number of contacts for the supply of diagnostic medications and bronchodilators are predicted to dominate the market.

North America Lymphangioleiomyomatosis (LAM )Market Country Level Analysis

The North America lymphangioleiomyomatosis (LAM )market is analysed and market size information is provided by product, method, wound type, end user.

The countries covered in the North America lymphangioleiomyomatosis (LAM) market report are the U.S., Canada, and Mexico.

• In 2021, U.S. is dominating due to the presence of the largest consumer market with high GDP. Moreover, the U.S. has the highest household spending in the world and offers trade agreements with several countries making it the largest market for consumer products, including dandruff treatment products, due to the presence of major market players and increased technological advancement in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

The Growth Potential for Lymphangioleiomyomatosis (LAM )in Emerging Economies and the Strategic Initiatives by Market Players are creating new Opportunities in the North America Lymphangioleiomyomatosis (LAM )Market.

North America lymphangioleiomyomatosis (LAM) market also provides you with detailed market analysis for every country growth in particular industry with the lymphangioleiomyomatosis (LAM )sales, impact of advancement in the lymphangioleiomyomatosis (LAM ), and changes in regulatory scenarios with their support for the lymphangioleiomyomatosis (LAM )market. The data is available for historic period 2019 to 2020.

Competitive Landscape and North America Lymphangioleiomyomatosis (LAM )Market Share Analysis

O panorama competitivo do mercado norte-americano de linfangioleiomiomatose (LAM) fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produtos, aprovações de produtos, patentes, largura do produto, e respiração, domínio da aplicação, curva da linha de vida da tecnologia. Os dados acima fornecidos estão apenas relacionados com o foco da empresa relacionado com o mercado da linfangioleiomiomatose (LAM).

As principais empresas que fornecem linfangioleiomiomatose (LAM) são a Pfizer Inc, Intas Pharmaceuticals Ltd, Apotex Inc, Amneal Pharmaceuticals LLC, Dr. Reddy's Laboratories Ltd, Novartis AG, Hikma Pharmaceuticals PLC, Teva Pharmaceutical USA Inc, Zydus Pharmaceuticals, Inc, TransMedics Group Inc . , Terumo Corporation, Home Oxygen Company, Inogen, Paragonix Technologies, Inc, Care Dx, XVIVO, Taj Pharmaceuticals Limited, PulmOne Advanced Medical Devices, Morgan Scientific entre outros.

Os analistas DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.

As iniciativas estratégicas dos participantes do mercado, juntamente com os novos avanços tecnológicos para a linfangioleiomiomatose (LAM) da América do Norte, estão a preencher a lacuna para o tratamento de doenças pulmonares crónicas.

Por exemplo,

• Em fevereiro de 2021, o medicamento para rejeição de órgãos Apotex Inc (uma subsidiária da Apotex Pharmaceuticals Holdings, Inc) emitiu o recall voluntário em todo o país da injeção de enoxaparina sódica, USP, devido à rotulagem incorreta das marcações de medição do barril da seringa. A injeção de enoxaparina sódica é utilizada para curar a embolia pulmonar. A recolha atrasaria ainda mais a produção do medicamento genérico e o tratamento dos doentes com TSC –LAM

A colaboração, as joint ventures e outras estratégias do player de mercado estão a melhorar o mercado da empresa no mercado da linfangioleiomiomatose (LAM), que também oferece o benefício para a organização melhorar a sua oferta para o mercado da linfangioleiomiomatose (LAM) da América do Norte.

SKU-63808